{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:48:17Z","timestamp":1787014097562,"version":"build-2736575974"},"reference-count":129,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The obesity epidemic has been linked to the worsening diabetes epidemic. Despite this, weight reduction for individuals with obesity is seen as a secondary, or even tertiary, consideration in the treatment of type 2 diabetes (T2D). The aim of this review is to examine the benefits of weight management in individuals with T2D. A literature review of current available published data on the benefits of weight reduction in individuals with T2D was conducted. In individuals with T2D who have obesity or overweight, modest and sustained weight reduction results in improvement in glycaemic control and decreased utilization of glucose\u2010lowering medication. A total body weight loss of 5% or higher reduces HbA1c levels and contributes to mitigating risk factors of cardiovascular disease, such as hyperlipidaemia and hypertension, as well as other disease\u2010related complications of obesity. Progressive improvements in glycaemic control and cardiometabolic risk factors can occur when the total body weight loss increases to 10% or more. In the approach to treating patients with T2D and obesity, prioritizing weight management and the use of therapeutics that offer glycaemic control as well as the additional weight loss should be emphasized given their potential to attenuate the progression and severity of T2D.<\/jats:p>","DOI":"10.1111\/dom.14764","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T02:36:07Z","timestamp":1652322967000},"page":"1411-1422","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Examining the evidence for weight management in individuals with type 2 diabetes"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0822-0860","authenticated-orcid":false,"given":"W. Timothy","family":"Garvey","sequence":"first","affiliation":[{"name":"University of Alabama at Birmingham UAB Diabetes Research Center  Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3252-5026","authenticated-orcid":false,"given":"Guillermo E.","family":"Umpierrez","sequence":"additional","affiliation":[{"name":"Emory University  Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia P.","family":"Dunn","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita Y. M.","family":"Kwan","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8054-2544","authenticated-orcid":false,"given":"Oralee J.","family":"Varnado","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1584-8309","authenticated-orcid":false,"given":"Manige","family":"Konig","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Levine","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,5,30]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1909301"},{"key":"e_1_2_12_3_1","volume-title":"National Diabetes Statistics Report, 2020","author":"Centers for Disease Control and Prevention","year":"2020"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0447"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30058-2"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S009"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.4158\/CS-2019-0472"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S008"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.12.013"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2018.10.011"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S009"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP161365.GL"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP161688.PS"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.307591"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2415"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30162-0"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-1518"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2021.06.002"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.9676"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0930"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.04.018"},{"key":"e_1_2_12_23_1","article-title":"All\u2010cause mortality over 16\u2009years in Look AHEAD","volume":"69","author":"Wing RR","year":"2020","journal-title":"Diabetes."},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci21-0034"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33102-1"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0714"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002985"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000070157.96264.13"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012512"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1212914"},{"key":"e_1_2_12_31_1","first-page":"1","article-title":"Patient\u2010reported outcomes in patients with type 2 diabetes treated with tirzepatide or placebo (SURPASS\u20101)","volume":"64","author":"Boye K","year":"2021","journal-title":"Diabetologia"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa2032271"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2015.53304"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67528-9"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108984"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12306"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066224"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.585396"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S136639"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1476332"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpu292"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70156-1"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4253-z"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30068-3"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30117-0"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.2337\/ds17-0012"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2021.101390"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12567"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-3023"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.6820"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.21055"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.12.014"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1177\/26317745211019156"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14215"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1057"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-2481"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043690"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0234"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v7.i17.354"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4669-0"},{"key":"e_1_2_12_62_1","first-page":"453","article-title":"SGLT\u20102 inhibitors and their potential in the treatment of diabetes","volume":"6","author":"Rosenwasser RF","year":"2013","journal-title":"Diabetes Metab Syndr Obes."},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-014-0089-4"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.88"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2260"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00686-z"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.05.037"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32590-X"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14641"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30267-4"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30066-X"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30023-8"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.2337\/ds16-0026"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1507"},{"key":"e_1_2_12_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13230"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.1995.tb00650.x"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2019.04.010"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.028136"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13847"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395"},{"key":"e_1_2_12_81_1","unstructured":"NordiskN.Saxenda Prescribing Information 2020.https:\/\/www.novo-pi.com\/saxenda.pdf. Accessed April 14 2021."},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.140"},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.2337\/ds17-0044"},{"key":"e_1_2_12_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2016.175"},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.7.1123"},{"key":"e_1_2_12_87_1","unstructured":"AstraZenenca.AstraZeneca Pipeline.https:\/\/www.astrazeneca.com\/our-science\/pipeline.html. Accessed August 23 2020."},{"key":"e_1_2_12_88_1","unstructured":"Eli Lilly and Company.Lilly Pipeline.2020.https:\/\/www.lilly.com\/discovery\/clinical-development-pipeline#\/. Accessed August 23 2020."},{"key":"e_1_2_12_89_1","unstructured":"OPKO Health.Opko Pipeline.https:\/\/www.opko.com\/what-we-do\/our-research\/opk88003-oxyntomodulin-analog. Accessed August 23 2020."},{"key":"e_1_2_12_90_1","unstructured":"Novo NordiskNovo Nordisk Pipeline.https:\/\/www.novonordisk.com\/science-and-technology\/r-d-pipeline.html. Accessed December 11 2020."},{"key":"e_1_2_12_91_1","unstructured":"Boehringer Ingelheim and Zealand Pharma Advance Dual\u2010Acting GLP\u20101\/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity\/Diabetes.2019.https:\/\/www.boehringer-ingelheim.com\/press-release\/collaboration-zealand-pharma-advances-phase-ii. Accessed April 14 2021."},{"key":"e_1_2_12_92_1","unstructured":"Pfizer.Pfizer Pipeline.2021.https:\/\/www.pfizer.com\/science\/internal-medicine\/pipeline. Accessed April 22 2021."},{"key":"e_1_2_12_93_1","unstructured":"SCOHIA PHARMA.Scohia Pipeline.2021.https:\/\/www.scohia.com\/eng\/sys\/pipeline\/. Accessed April 22 2021."},{"key":"e_1_2_12_94_1","unstructured":"Carmot TherapeuticsC.Carmot Pipeline.2021.http:\/\/carmot-therapeutics.us\/pipeline\/. Accessed April 22 2021."},{"key":"e_1_2_12_95_1","unstructured":"Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes.2021.https:\/\/www.prnewswire.com\/news-releases\/tirzepatide-achieved-superior-a1c-and-body-weight-reductions-across-all-three-doses-compared-to-injectable-semaglutide-in-adults-with-type-2-diabetes-301239948.html. Accessed March 17 2021."},{"key":"e_1_2_12_96_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519"},{"key":"e_1_2_12_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00981-0"},{"key":"e_1_2_12_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01324-6"},{"key":"e_1_2_12_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01443-4"},{"key":"e_1_2_12_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02188-7"},{"key":"e_1_2_12_101_1","doi-asserted-by":"crossref","unstructured":"DahlD OnishiY NorwoodP HuhR PatelH Rodr\u00edguez\u00c1.80\u2010LB: tirzepatide a dual GIP\/GLP\u20101 receptor agonist is effective and safe when added to basal insulin for treatment of type 2 diabetes (SURPASS\u20105).Diabetologia.2021;64:1\u2010380:80\u2010LB.","DOI":"10.2337\/db21-80-LB"},{"key":"e_1_2_12_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01919-X"},{"key":"e_1_2_12_103_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP15672.GLSUPPL"},{"key":"e_1_2_12_104_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-4886-1"},{"key":"e_1_2_12_105_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCN.0b013e31819846b9"},{"key":"e_1_2_12_106_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S39739"},{"key":"e_1_2_12_107_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0934-x"},{"key":"e_1_2_12_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.016"},{"key":"e_1_2_12_109_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02696.x"},{"key":"e_1_2_12_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2018.12.001"},{"key":"e_1_2_12_111_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1473"},{"key":"e_1_2_12_112_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-017-0262-y"},{"key":"e_1_2_12_113_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0007"},{"key":"e_1_2_12_114_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.28.5.w822"},{"key":"e_1_2_12_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107730"},{"key":"e_1_2_12_116_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0093"},{"key":"e_1_2_12_117_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12971"},{"key":"e_1_2_12_118_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-s229"},{"key":"e_1_2_12_119_1","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v5.i6.854"},{"key":"e_1_2_12_120_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.33457"},{"key":"e_1_2_12_121_1","unstructured":"Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes.2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04982575. Accessed December 14 2021."},{"key":"e_1_2_12_122_1","unstructured":"Mellitus ASoLiPWTD.2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05048719. Accessed December 14 2021."},{"key":"e_1_2_12_123_1","unstructured":"Once\u2010weekly semaglutide 2.0 mg demonstrates superior reduction in HbA1c vs once\u2010weekly semaglutide 1.0 mg in people with type 2 diabetes in the SUSTAIN FORTE trial.2020.https:\/\/www.novonordisk.com\/news-and-media\/news-and-ir-materials\/news-details.html?id=34777. Accessed April 22 2021."},{"key":"e_1_2_12_124_1","unstructured":"Carmot Therapeutics.2021.http:\/\/carmot-therapeutics.us\/pipeline\/. Accessed April 16 2021."},{"key":"e_1_2_12_125_1","unstructured":"ClinicalTrials.gov.A Study of CT\u2010388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus.https:\/\/clinicaltrialsgov\/ct2\/show\/NCT04838405. Accessed December 8 2021."},{"key":"e_1_2_12_126_1","unstructured":"ClinicalTrials.gov.A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480\u20100389 Works in People With Type 2 Diabetes.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05144984. Accessed December 7 2021."},{"key":"e_1_2_12_127_1","unstructured":"ClinicalTrials.gov.A Study of LY3437943 in Participants Who Have Obesity or Are Overweight.https:\/\/clinicaltrialsgov\/ct2\/show\/NCT04881760. Accessed December 8 2021."},{"key":"e_1_2_12_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30726-8"},{"key":"e_1_2_12_129_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz047"},{"key":"e_1_2_12_130_1","unstructured":"ClinicalTrials.gov.A Phase 1 Study of DD01 in Overweight\/Obese Subjects With T2DM and NAFLD.https:\/\/clinicaltrialsgov\/ct2\/show\/NCT04812262. Accessed December 7 2021."}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14764","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14764","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14764","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:36:54Z","timestamp":1761867414000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,30]]},"references-count":129,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1111\/dom.14764"],"URL":"https:\/\/doi.org\/10.1111\/dom.14764","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,30]]},"assertion":[{"value":"2022-01-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}